Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
The purpose of the study is to demonstrate the safety and efficacy of Leuprolide Acetate for Injectable Suspension 22.5 mg in reducing serum testosterone to castrate levels in patients with prostate cancer.
Prostate Cancer
DRUG: Leuprolide Acetate for Injectable Suspension
The percentage of responders who attain and maintain castrate levels of serum testosterone, From Day 28 to Day 168.
Safety as shown through laboratory parameters, Hematology, chemistry and urinalysis, Day 0 - Day 168|Leuprolide serum profiles following administration study drug product., Leuprolide levels (ng/dL) measured at designated time points to determine a pharmacokinetic profile for the product., Day 0 - Day 168|Safety as shown through reported adverse events, Day 0 -168
This study is an open-label, multi-center study in which a minimum of 165 patients will receive one (1) of three (3) lots of Oakwood Laboratories' Leuprolide Acetate for Injectable Suspension 22.5 mg for two cycles. A subset of patients (minimum of 12) will be assigned to each lot (A, B or C) and will have additional blood sampling to characterize leuprolide release kinetics for each dose administered.